| scholarly article | Q13442814 |
| P356 | DOI | 10.1023/A:1008331111654 |
| P698 | PubMed publication ID | 10643537 |
| P2093 | author name string | L Crinò | |
| H von der Maase | |||
| L Dogliotti | |||
| L Andersen | |||
| S Weinknecht | |||
| P2860 | cites work | Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 |
| Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study | Q33498199 | ||
| Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer | Q33498591 | ||
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 | ||
| A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 | ||
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
| Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 | ||
| Cancer statistics, 1996. | Q50610104 | ||
| A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 | ||
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 | ||
| P433 | issue | 12 | |
| P921 | main subject | cisplatin | Q412415 |
| transitional cell carcinoma | Q2501186 | ||
| phase II clinical trial | Q42824440 | ||
| P304 | page(s) | 1461-1465 | |
| P577 | publication date | 1999-12-01 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial | |
| P478 | volume | 10 |
| Q39514318 | A conventional preclinical schedule of cisplatin is more effective than a metronomic frequent bolus schedule for urothelial carcinoma |
| Q43777231 | A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer |
| Q45090161 | A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer |
| Q43634503 | A phase II study of gemcitabine and cisplatin combination as induction chemotherapy for untreated locally advanced cervical carcinoma |
| Q46033801 | A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. |
| Q36729145 | Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. |
| Q53250202 | Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. |
| Q37789085 | Current chemotherapeutic options for the treatment of advanced bladder cancer: A review |
| Q37038897 | Current optimal chemotherapy for advanced urothelial cancer |
| Q35128721 | Current therapeutic strategies for invasive and metastatic bladder cancer. |
| Q80296413 | Determining the optimal treatment for advanced bladder cancer |
| Q37874887 | Diagnosis and management of urothelial carcinoma of the bladder |
| Q40708483 | Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer |
| Q33978838 | Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer |
| Q33364779 | Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study |
| Q37896172 | Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma |
| Q33332660 | Gemcitabine in locally advanced and/or metastatic bladder cancer |
| Q33347231 | Gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer: a prospective observational study |
| Q33344322 | Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens |
| Q33356968 | Gemcitabine/cisplatin vs. MVAC. 5 year survival outcome of the phase III study of chemotherapy of advanced urothelial carcinoma in Germany |
| Q33978846 | Gemcitabine/paclitaxel-based three-drug regimens in advanced urothelial cancer |
| Q35192415 | Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial |
| Q42608319 | Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series |
| Q44243828 | Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer |
| Q37523855 | Management of bladder cancer: current and emerging strategies |
| Q46205666 | Metastases from urethelial carcinoma: role of chemotherapy |
| Q33377834 | Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy |
| Q33366042 | Neoadjuvant gemcitabine and cisplatin followed by radical surgery in (bulky) squamous cell carcinoma of cervix stage IB2. |
| Q35192424 | New drugs and new approaches in metastatic bladder cancer |
| Q35098007 | Overview of bladder cancer trials in the European Organization for Research and Treatment |
| Q33357713 | Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. |
| Q33341273 | Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer |
| Q44124156 | Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. |
| Q45972761 | Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder. |
| Q27010323 | Role of systemic chemotherapy in urothelial urinary bladder cancer |
| Q48898011 | Salvage therapy for recurrence of bladder cancer: do we need a uniform approach? |
| Q60049823 | The continuing role of chemotherapy in the management of advanced urothelial cancer |
| Q35021331 | The role of systemic chemotherapy in the management of muscle-invasive bladder cancer |
| Q58694390 | Update on chemotherapy in the treatment of urothelial carcinoma |
| Q37821892 | Vinflunine in the treatment of advanced bladder cancer |
| Q78898958 | [Advanced bladder cancer: new therapeutic strategies] |
Search more.